Comparative effectiveness of H7N9 vaccines in healthy individuals

Figures & data

Figure 1. Flow diagram of the selection process of studies for the meta-analysis.

Table 1. Characteristics of studies identified.

Study	Design	Clinical Trials Registration	No. of participants	Age	Vaccine Type	HA Antigen Dose	Adjuvant	Main outcome	Jadad score
Fries et al., 2013^Citation21	RCT, double-blind	NCT01897701	284	≥ 18	VLP	placebo, 5 μg, 15 μg, 45 μg	ISCOMATRIX	HI, AE	5
Bart et al.^Citation22	randomized, observer-blind	NCT01928472	402	18–64	inactivated subunit	3.75 μg, 7.5 μg, 15 μg	MF59	HI, MN, AE	4
Mulligan et al., 2014^Citation23	randomized, double-blind	NCT01938742	700	19–64	inactivated split	3.75 μg, 7.5 μg, 15 μg, 45 μg	MF59	HI, MN, AE	5
Jackson et al.^Citation24	randomized, double-blind	NCT01942265	980	19–64	inactivated split	3.75 μg, 7.5 μg, 15 μg, 45 μg	MF59, AS03	HI, MN, AE	5
Madan et al., 2016^Citation25	RCT, observer-blind	NCT01999842	420	18–64	inactivated split	placebo, 3.75 μg, 7.5 μg, 15 μg	AS03	HI, AE	4
Wu et al.^Citation26	randomized, open-label	NCT02436928	200	20–60	inactivated whole-virion	15 μg, 30 μg	Al(OH)3	HI, MN, AE	3
Sobhanie et al.^Citation20	randomized, open-label	NCT01995695	32	18–49	LAIV (prime) inactivated subvirion (boost)	10^7.0 FFU (prime) 30 μg (boost)		HI, MN, AE	3
		NCT02274545	17	50–70
Rudenko et al.^Citation27	RCT, double-blind	NCT02480101	40	18–49	LAIV	placebo, 7.5 log10 EID50		HI, MN, AE	5
DeZure et al.^Citation28	randomized, open-label	NCT02206464	30	18–60	DNA or inactivated subunit (prime) inactivated subunit (boost)	4 mg or with 45 μg (prime) 45 μg (boost)		HI, MN, AE	3

RCT: randomized controlled trial; VLP: virus-like particles; HI: hemagglutination inhibition; MN: microneutralization; AE: adverse events.

Figure 2. Forest plots for comparing the immunogenicity of adjuvanted verses non-adjuvanted H7N9 vaccines.

Figure 3. Forest plots for comparing the immunogenicity of adjacent dose groups of H7N9 vaccines.

Figure 4. Forest plots for comparing local and systemic adverse events of adjuvanted verses non-adjuvanted H7N9 vaccines.

Figure 5. Forest plots for comparing local and systemic adverse events of adjacent dose groups of H7N9 vaccines.

Fries LF, Smith GE, Glenn GM. 2013. A Recombinant Viruslike Particle Influenza A (H7N9) vaccine. N Engl J Med. 369:2564–2566. doi:10.1056/NEJMc1313186.

 PubMed Web of Science ®Google Scholar

Bart SA, Hohenboken M, Cioppa GD, Narasimhan V, Dormitzer PR, Kanesa-Thasan N. 2014. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med. 6:234ra55. doi:10.1126/scitranslmed.3008761.

 PubMed Web of Science ®Google Scholar

Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, et al. Serological responses to an avian influenza AH7N9 vaccine mixed at the point-of-use with MF59 adjuvant a randomized clinical trial. JAMA. 2014;312:1409–1419. doi:10.1001/jama.2014.12854.

 PubMed Web of Science ®Google Scholar

Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, Berry AA, Graham I, Atmar RL, Creech CB, et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: A randomized clinical trial. JAMA. 2015;314:237–246. doi:10.1001/jama.2015.7916.

 PubMed Web of Science ®Google Scholar

Madan A, Segall N, Ferguson M, Frenette L, Kroll R, Friel D, Soni J, Li P, Innis BL, Schuind A. 2016. Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults. J Infect Dis. 214:1717–1727. doi:10.1093/infdis/jiw414.

 PubMed Web of Science ®Google Scholar

Wu UI, Hsieh SM, Lee WS, Wang NC, Kung HC, Ou TY, Chen FL, Lin TY, Chen YC, Chang SC. 2017. Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults A phase I/II,prospective, randomized, open-label trial. Vaccine. 35:4099–4104. doi:10.1016/j.vaccine.2017.06.044.

 PubMed Web of Science ®Google Scholar

Sobhanie M, Matsuoka Y, Jegaskanda S, Fitzgerald T, Mallory R, Chen Z, Luke C, Treanor J, Subbarao K. 2016. Evaluation of the safety and immunogenicity of a candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9). J Infect Dis. 213:922–929. doi:10.1093/infdis/jiv526.

 PubMed Web of Science ®Google Scholar

Rudenko L, Isakova-Sivak I, Naykhin A, Kiseleva I, Stukova M, Erofeeva M, Korenkov D, Matyushenko V, Sparrow E, Kieny MP. 2016. H7N9 live attenuated influenza vaccine in healthy adults a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 16:303–310. doi:10.1016/S1473-3099(15)00378-3.

 PubMed Web of Science ®Google Scholar

DeZure AD, Coates EE, Hu Z, Yamshchikov GV, Zephir KL, Enama ME, Plummer SH, Gordon IJ, Kaltovich F, Andrews S, et al. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. NPJ Vaccines. 2017;2:15. doi:10.1038/s41541-017-0016-6.

 PubMed Web of Science ®Google Scholar